Y-mAbs Therapeutics (YMAB) Expected to Announce Earnings on Tuesday

Y-mAbs Therapeutics (NASDAQ:YMAB) will likely be issuing its quarterly earnings data before the market opens on Tuesday, March 4th. Analysts expect Y-mAbs Therapeutics to post earnings of ($0.13) per share and revenue of $26.70 million for the quarter. Individual that are interested in registering for the company’s earnings conference call can do so using this link.

Y-mAbs Therapeutics Trading Up 2.5 %

Shares of NASDAQ YMAB opened at $5.56 on Friday. The business has a 50-day moving average of $6.58 and a 200-day moving average of $10.73. The firm has a market capitalization of $248.85 million, a price-to-earnings ratio of -10.29 and a beta of 0.67. Y-mAbs Therapeutics has a 12 month low of $5.28 and a 12 month high of $20.90.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the stock. Wedbush reissued an “outperform” rating and issued a $23.00 price target on shares of Y-mAbs Therapeutics in a report on Friday, January 10th. Oppenheimer started coverage on Y-mAbs Therapeutics in a research note on Monday, November 18th. They issued an “outperform” rating and a $23.00 target price on the stock. Brookline Capital Management began coverage on Y-mAbs Therapeutics in a research note on Thursday, December 5th. They set a “buy” rating and a $17.00 price target for the company. Finally, HC Wainwright reiterated a “buy” rating and set a $22.00 price objective on shares of Y-mAbs Therapeutics in a research report on Monday, January 13th. One analyst has rated the stock with a sell rating, seven have given a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $20.89.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.